Your browser doesn't support javascript.
loading
Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas.
Coyne, Geraldine O'Sullivan; Kummar, Shivaani; Meehan, Robert S; Do, Khanh; Collins, Jerry M; Anderson, Larry; Ishii, Kazusa; Takebe, Naoko; Zlott, Jennifer; Juwara, Lamin; Piekarz, Richard; Streicher, Howard; Sharon, Elad; Rubinstein, Larry; Voth, Andrea Regier; Lozier, Jay; Dull, Angie B; Wilsker, Deborah; Hinoue, Toshinori; Laird, Peter W; Ferry-Galow, Katherine V; Kinders, Robert J; Parchment, Ralph E; Doroshow, James H; Chen, Alice P.
Afiliação
  • Coyne GO; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Meehan RS; Current address: Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA.
  • Do K; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Collins JM; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
  • Ishii K; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA.
  • Takebe N; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
  • Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Juwara L; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Piekarz R; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Rubinstein L; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Voth AR; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA.
  • Lozier J; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Dull AB; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
  • Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Hinoue T; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Laird PW; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA.
  • Ferry-Galow KV; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA.
  • Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Doroshow JH; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Chen AP; Division of Cancer Treatment and Diagnosis, and Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Oncotarget ; 11(44): 3959-3971, 2020 Nov 03.
Article em En | MEDLINE | ID: mdl-33216844
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2020 Tipo de documento: Article